In short: Its Lingen (Germany) plant for Russian-designed VVER fuel is pitched as weaning Europe off Russian fuel, but uses "technology, expertise, and equipment designed and manufactured in Russia and sold to Framatome by Rosatom"; a lawsuit filed last week by German environmental groups seeks to overturn July's state approval. "One is using Russian help to do it in a plant that will not be ready for some considerable time."
Framatome is the French state-owned nuclear fuel maker (part of EDF). It is building capacity at its plant in Lingen, Germany, to produce fuel for the Russian-designed reactors that many European countries still run, and presents it as a way to wean Europe off Russian fuel.
The catch, raised by a lawsuit German environmental groups filed last week, is that the plant uses technology, know-how and equipment bought from Rosatom — the very Russian state company Europe is trying to stop depending on. The suit wants July's approval overturned and asks whether the setup fits sanctions and security rules; the German government's view is that it may not like it, but nothing in the law forbids it. Frostad's framing is unflattering: of the two companies offering Europe an exit from Russian fuel, this is the one "using Russian help to do it in a plant that will not be ready for some considerable time."
6:14Framatome presents it as an effort to wean European reactor owners off Russian fuel. But as a lawsuit filed last week by a group of German environmental organizations pointed out, the facility will use nuclear manufacturing technology, expertise, and equipment designed and manufactured in Russia and sold to Framatome by Rosatom, the same state-owned monopoly that would otherwise be supplying the fuel.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.